Diagnostic Decision Making for Androgen Patients

Learning Objectives

After completing this course, clinicians should be able to:

➀ Distinguish androgen-naïve physiology from androgen-exposed physiology and explain why that distinction changes all downstream diagnostic decisions.

➁ Perform a structured exposure history that captures compounds, timelines, dosing patterns, stacking, ancillary drugs, and recovery attempts.

➂ Recognize common endocrine and reproductive consequences of prior or ongoing testosterone and anabolic steroid exposure.

➃ Identify major cardiovascular, renal, hepatic, hematologic, dermatologic, and psychiatric complications associated with androgen exposure.

➄ Apply the ABCDS™ framework to the physical examination of androgen-exposed patients.

➅ Detect high-risk exposure patterns and clinical red flags that warrant escalation or specialist involvement.

➆ Integrate exposure history, endocrine status, physical findings, and systemic risk into a coherent diagnostic assessment.

Course Topics

The following topics will be covered in the course text, video, diagrams or downloadable documents:

➀ Diagnostic Framework for Androgen-Exposed Patients

➁ Clinical Presentation Patterns

➂ Exposure Stratification

➃ Comprehensive Exposure History

➄ Pharmacologic Impact on Suppression and Recovery

➅ Endocrine and Reproductive Consequences

➆ Multi-System Complication Screening

➇ Integrated Clinical History

➈ Physical Examination Using ABCDS™

⑩ High-Risk Red Flags

⑪ Diagnostic Integration

⑫ Collaboration and Continuity of Care

Video Lesson Takeaways

◉ In androgen-exposed patients, the first diagnostic distinction is whether the physiology being evaluated is androgen-naïve or altered by prior or ongoing testosterone, anabolic steroid, or mixed exposure.

◉ Exposure history is the most important diagnostic element because compound type, dosing pattern, stacking, ancillary drugs, and recovery attempts determine how symptoms, laboratory values, and suppression should be interpreted.

◉ Not all androgens are equivalent, and compounds such as nandrolone and trenbolone may produce more profound and prolonged HPG-axis suppression than standard testosterone exposure.

◉ Common endocrine and reproductive consequences of androgen exposure include persistent low testosterone after cessation, infertility, testicular atrophy, erectile dysfunction, and decreased libido.

◉ Multi-system complications are common and require deliberate screening across cardiovascular, renal, hepatic, hematologic, dermatologic, psychiatric, and endocrine domains.

◉ The ABCDS™ framework should be applied with heightened vigilance in androgen-exposed patients because physical examination may reveal cardiometabolic strain, erythrocytosis, renal risk, and systemic instability that history alone does not fully capture.

◉ High-risk red flags include long-term high-dose anabolic steroid exposure, persistent hypogonadism after cessation, severe erythrocytosis, structural heart disease, infertility with suppressed gonadotropins, and complex polypharmacy involving multiple iPEDs.

◉ Diagnostic decision making in this population requires a structured internal medicine–based approach that integrates exposure history, endocrine status, multi-organ system evaluation, and coordination with primary care and relevant specialists.

➀ Diagnostic Framework for Androgen-Exposed Patients

The first diagnostic question is whether the patient’s current endocrine picture is endogenous or pharmacologically altered, not what the total testosterone value is. In androgen-naïve patients, laboratory abnormalities are generally interpreted as reflections of baseline physiology unless another confounder is obvious. In androgen-exposed patients, the same abnormalities may reflect active administration, recent discontinuation, failed recovery, or a mixed state in which the hypothalamic-pituitary-gonadal (HPG) axis has not returned to baseline and may not be capable of doing so fully. The distinction between therapeutic testosterone exposure and anabolic steroid exposure is often primarily a matter of dose magnitude, with supraphysiologic dosing producing substantially greater suppression and systemic risk than physiologic replacement therapy. [1-4]

Suppressed gonadotropins may reflect exogenous androgen exposure rather than primary central disease. Low testosterone after cessation may represent transient suppression, prolonged suppression, or permanent dysfunction, and those are not interchangeable diagnoses. Patient evaluation starts by identifying what kind of physiology is being assessed before trying to explain the concern.

➁ Clinical Presentation Patterns

Evaluation begins with the patient’s stated chief concern and reason for seeking care. The presenting symptoms are often familiar, but the mechanism underneath them is not. Fatigue, loss of libido, erectile dysfunction, infertility, depressed mood, anxiety, irritability, cognitive dysfunction, reduced vitality, loss of muscle, increased body fat, and sleep disturbance all appear in androgen-exposed patients and androgen-naïve patients. Cognitive complaints such as “brain fog” may arise from steroid withdrawal physiology and should not automatically be interpreted as primary hypogonadism. What separates the two groups is timing, exposure context, and the probability that the endocrine system has already been altered by prior use. Common presenting concerns include loss of libido after steroid discontinuation, erectile dysfunction, fertility concerns, mood instability, and post-cycle “crash” symptoms. Some patients also present with significant psychosocial distress related to impaired dating, intimacy, or reproductive confidence following anabolic steroid exposure. [1-4,6]

➂ Exposure Stratification

Every patient should be categorized early as androgen-naïve, therapeutically testosterone-exposed, supraphysiologically AAS-exposed, or mixed-exposure. An androgen-naïve patient generally starts with intact endogenous physiology unless primary pathology exists. A therapeutically exposed patient usually has expected suppression within a framework that was at least intended to be monitored. A supraphysiologically exposed patient should be assumed to carry greater suppression, greater cumulative risk, and a much higher chance that the history is incomplete, simplified, or partly inaccurate. Mixed exposure deserves special caution. These patients often cycle between nominally therapeutic and clearly nontherapeutic states over time, which makes the physiology harder to reconstruct and the risk easier to underestimate. [1-4]

➃ Comprehensive Exposure History

A useful exposure history has to define when use began, why it began, how it evolved, what compounds were used, what doses were taken, how long the patient stayed on, how they cycled or failed to cycle off, what recovery attempts were made, and what the response to those attempts actually was. Clinicians should understand the three major anabolic steroid families; testosterone-derived, nandrolone-derived (19-nors), and DHT-derived compounds because their pharmacologic behavior differs. [3,6-8]

A vague history of “I’ve used testosterone and some other compounds” is not medically usable. Exposure history should also identify cycling behaviors such as blast-and-cruise patterns, where supraphysiologic cycles alternate with ongoing testosterone maintenance. Patients frequently report that early steroid cycles appeared to recover normally, while repeated cycles progressively reduced the likelihood of full endogenous hormonal recovery. Clinicians should recognize the major compound families encountered in practice, including testosterone-derived esters, nandrolone-derived compounds, and DHT-derived agents as these agents can have different characteristics. Ancillary drugs such as aromatase inhibitors, SERMs, hCG, thyroid hormones, insulin, growth hormone, SARMs, and diuretics should be actively screened for during exposure reconstruction [3,4].

➄ Pharmacologic Impact on Suppression and Recovery

Suppression is a question of which compounds were used, at what dose, in what combinations, and for how long. That distinction matters clinically because different drugs do not produce the same recovery landscape. Testosterone can certainly suppress the axis, but long-term high-dose exposure, repeated cycling, and blast-and-cruise behavior create a different problem than short-term, controlled replacement. [3,4,7]

The clinician should assess recovery through time since cessation, prior post-cycle attempts, gonadotropin status, fertility goals, and the broader pattern of physiologic improvement or failure. The clinician should also determine whether post-cycle therapy was attempted and what agents were used. Clinicians should avoid instructing abrupt discontinuation of anabolic steroids without evaluation and follow-up, as withdrawal after prolonged androgen exposure may produce significant physiologic and psychiatric instability.

➅ Endocrine and Reproductive Consequences

Anabolic steroid–induced hypogonadism (ASIH) is one of the most common endocrine presentations in androgen-exposed patients and must be actively considered during evaluation. Persistent low testosterone after cessation, erectile dysfunction, decreased libido, infertility, azoospermia or oligospermia, and testicular atrophy are direct outcomes of suppression and failed or incomplete recovery. [3,5-8]

Reproductive consequences often change the patient’s motivation more than cosmetic or performance consequences ever did. A patient may tolerate acne, body-composition volatility, mood instability, or adverse lipids for years and still remain unconcerned. Infertility or sexual dysfunction changes the problem immediately. It forces the clinician to think beyond symptom treatment and toward axis status, reversibility, and long-term reproductive implications. That is why fertility history is one of the clearest markers of biological consequence.

➆ Multi-System Complication Screening

Androgen exposure affects many systems. Cardiovascular complications such as hypertension, atherogenic dyslipidemia, cardiomyopathy, and coronary disease risk belong in the core evaluation. Renal screening should consider renal injury related to steroid exposure, which may include focal segmental glomerulosclerosis and progressive chronic kidney disease especially when high-dose exposure is layered with dehydration practices, diuretics, stimulants, or extreme body-composition manipulation. Hepatic screening matters most with oral anabolic agents, where enzyme elevation and cholestatic injury can become clinically significant. Hematologic screening must remain alert to androgen-induced erythrocytosis. Psychiatric screening should assess mood instability, aggression, anxiety, depression, dependence patterns, and obsessive body-dysmorphic behavior. Dermatologic findings such as severe acne, seborrhea, and hair loss may serve as accessible markers of broader androgen burden. [3,4,6-9]

What separates a strong screen from a superficial one is prioritization. The clinician should leave the assessment knowing which domains are immediately dangerous, which require longitudinal surveillance, and which are present but not yet urgent. A mildly abnormal HDL is not the same clinical problem as structural heart disease or progressive psychiatric instability. Severe mood instability and suicidality may occur during steroid withdrawal or failed recovery and should be actively screened during assessment. This section of the workup should therefore function as a hierarchy of risk.

➇ Integrated Clinical History

The integrated history must connect symptoms to exposure across time. Symptom chronology relative to androgen use, pre-exposure baseline health, recovery attempts after discontinuation, and current hormonal status are the timeline that explains the patient’s physiology. [3,6-8]

A good history identifies turning points. When did the patient first feel altered? Did symptoms improve during active exposure and worsen off-cycle? Was there ever a period of true recovery, or has the patient been cycling through suppression and attempted recovery without ever returning to baseline? Was fertility normal before exposure? Did sexual dysfunction begin only after cessation?

➈ Physical Examination Using ABCDS™

The ABCDS™ framework systematically evaluates glycemic health, blood pressure and cardiovascular status, hematologic effects such as androgen-induced erythrocytosis, and systemic screening including mental health and cancer risk. [1-3]The physical examination is used to identify where exposure has altered the body in clinically meaningful ways. In many patients, those findings provide objective evidence of burden that the history alone cannot fully capture.

➉ High-Risk Red Flags

Some features should immediately move the patient into a higher-risk category. Long-term high-dose AAS exposure, persistent hypogonadism after cessation, severe erythrocytosis, structural heart disease, infertility with suppressed gonadotropins, and complex polypharmacy involving multiple IPEDs all deserve more urgent and more careful evaluation than routine low-testosterone concerns. [3,6-8]

These red flags suggest either severe cumulative exposure, incomplete reversibility, clinically meaningful organ-system injury, or all three. These patients require tighter interpretation, clearer counseling, and more deliberate coordination than standard outpatient hormone follow-up.

⑪ Diagnostic Integration

The clinician must synthesize detailed exposure history, endocrine status, multi-organ system evaluation, and laboratory or imaging data into a coherent interpretation. That synthesis should answer several questions: how suppressed is the HPG axis, what risks are immediate, what risks are long-term, and what remains unknowable because the exposure history is incomplete or the physiology is still unstable. Recovery of the hypothalamic-pituitary-gonadal axis after steroid exposure may remain incomplete or permanently altered. In some individuals, prolonged exposure to supraphysiologic androgens may also alter neuroendocrine expectations, leaving physiologic testosterone levels subjectively inadequate despite apparent laboratory recovery. [3,4,7,8]

This is the stage where Testosteronology® becomes medical judgment rather than number reading. A common error is premature closure, where the clinician identifies low testosterone after steroid use and moves too quickly to treatment without resolving whether the condition is transient, partially reversible, permanently altered, or confounded by broader medical problems. Strong diagnostic integration prevents that mistake. It organizes uncertainty instead of pretending uncertainty is absent.

⑫ Collaboration and Continuity of Care

These patients often require a multidisciplinary treatment approach, but that does not mean responsibility should become diffuse. The physician evaluating androgen exposure must still own the diagnostic frame and understand how the different risk domains connect. [1-8]

Cardiology may be needed for structural heart disease or exercise intolerance that no longer fits simple conditioning status. Nephrology may be needed when creatinine, proteinuria, or long-term renal stress becomes clinically significant. Reproductive input may become essential when fertility restoration is a priority. Mental health support may be just as important when mood instability, compulsive body-image patterns, or dependence behavior begin to shape the course of care.

Continuity is what keeps the case from resetting every time the patient sees a new provider. These patients often move between hormone clinics, primary care, underground advice networks, and specialist consultations. If the documentation does not preserve the real exposure history, the current interpretation, and the major unresolved questions, the next clinician may repeat the same errors from the beginning.

COURSE SUMMARY

Course 5 establishes that androgen-exposed patients cannot be evaluated as though they were hormonally naïve. Exposure history is the most critical diagnostic element because it defines the physiology the clinician is actually seeing. Compound class, dosing pattern, stacking behavior, ancillary drug use, and recovery history all shape suppression, reversibility, fertility implications, and long-term risk. Endocrine findings must therefore be interpreted alongside cardiovascular, renal, hepatic, hematologic, dermatologic, reproductive, and psychiatric screening rather than in isolation. The practical result is a more accurate assessment, stronger risk recognition, and a more defensible internal medicine–based approach to patients exposed to testosterone and anabolic steroids. [1-8]

REFERENCES

Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. doi:10.1016/j.juro.2018.03.115
Anawalt BD. Diagnosis and management of anabolic androgenic steroid use. J Clin Endocrinol Metab. 2019;104(7):2490-2500. doi:10.1210/jc.2018-01806
Handelsman DJ. Androgen misuse and abuse. Endocr Rev. 2021;42(4):457-501. doi:10.1210/endrev/bnab001
Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline. Updated 2024.
Khera M, Torres LO, Grober ED, et al. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine. Sex Med Rev. 2025;13(4):548-573.
Smit DL, Biermasz NR, de Ronde W. Approach to the young male patient who abuses androgens. J Clin Endocrinol Metab. 2025;111(1):e292-e307.
Solanki P, Gilbert K, Pugh PJE. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocr Connect. 2023;12(12).
Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, et al. Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation. 2025;151(12):828-834. doi:10.1161/CIRCULATIONAHA.124.071117

Diagnostic Decision Making: History and Physical Examination for Patients on Androgens and iPEDs

Course Overview

Learning Objectives

Course Topics

005 Diagnostic Decision Making: History and Physical Examination for Patients on Androgens and iPEDs

Video Lesson Takeaways

➀ Diagnostic Framework for Androgen-Exposed Patients

➁ Clinical Presentation Patterns

➂ Exposure Stratification

➃ Comprehensive Exposure History

➄ Pharmacologic Impact on Suppression and Recovery

➅ Endocrine and Reproductive Consequences

➆ Multi-System Complication Screening

➇ Integrated Clinical History

➈ Physical Examination Using ABCDS™

➉ High-Risk Red Flags

⑪ Diagnostic Integration

⑫ Collaboration and Continuity of Care

Recommended Grand Rounds Case Reviews